NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
NCT06734130 2026-04-01
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06401980 2026-03-30
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting